Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach.

Haematologica
John M Bennett, Attilio Orazi

Abstract

Members of the French-American-British Cooperative Leukemia Working Group met to review cases of aplastic anemia, hypocellular myelodysplastic syndrome and hypocellular acute myeloid leukemia. Criteria were proposed and modified following three workshops. Additional input was obtained from another hematopathologist with a special interest in bone marrow histology and immunohistochemistry. Guidelines were recommended based on the workshop results as well as additional studies including selective immunohistochemistry, flow cytometry and cytogenetics.

References

Aug 1, 1986·Pathology, Research and Practice·C De Wolf-PeetersR L Verwilghen
Aug 1, 1994·Leukemia Research·N Tuzuner, J M Bennett
Nov 1, 1995·British Journal of Haematology·N TuzunerJ M Bennett
Jan 9, 2008·Seminars in Hematology·Charlotte M Niemeyer, Irith Baumann
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elaine M SloandJohn Barrett

❮ Previous
Next ❯

Citations

Aug 12, 2009·Journal of Hematopathology·Jon van der Walt
Nov 28, 2012·Bone Marrow Transplantation·A Tichelli, J C W Marsh
Nov 21, 2012·Bone Marrow Transplantation·A RovóUNKNOWN SAA-WP EBMT
Jan 27, 2012·Journal of Pediatric Hematology/oncology·Masaki YamamotoNobuhiro Suzuki
Sep 9, 2010·Applied Immunohistochemistry & Molecular Morphology : AIMM·Zoltán Tóth, Veronika Czoma
Dec 10, 2013·Hematology·Judith C W Marsh, Austin G Kulasekararaj
Aug 12, 2010·Indian Journal of Pathology & Microbiology·Rahul Bhargava, Bakul I Dalal
Aug 1, 2014·Current Hematologic Malignancy Reports·Lukasz P Gondek, Amy E DeZern
Nov 5, 2013·Human Pathology·Natalia GolardiDavid R Czuchlewski
Jan 16, 2016·American Journal of Hematology·Naseema GangatAyalew Tefferi
Nov 17, 2015·British Journal of Haematology·Sally B KillickUNKNOWN British Society for Standards in Haematology
Sep 29, 2011·Seminars in Oncology·Mario CazzolaLuca Malcovati
Sep 29, 2011·Seminars in Oncology·Rodrigo T Calado
Apr 3, 2010·Hematology/oncology Clinics of North America·Mario Cazzola, Luca Malcovati
Aug 14, 2009·British Journal of Haematology·Judith C W MarshUNKNOWN British Committee for Standards in Haematology
Feb 22, 2012·British Journal of Haematology·Sujith Samarasinghe, David K H Webb
Jul 16, 2010·International Journal of Laboratory Hematology·C C YinC E Bueso-Ramos
Apr 17, 2016·International Journal of Hematology·J C W Marsh, G J Mufti
Jan 1, 2014·British Journal of Haematology·Sally B KillickUNKNOWN British Committee for Standards in Haematology
Nov 3, 2009·Histopathology·Bridget S Wilkins, David M Clark
May 16, 2015·International Journal of Laboratory Hematology·E E TorlakovicUNKNOWN International Council for Standardization in Haematology
Feb 19, 2013·Cell·Eda YildirimJeannie T Lee
Sep 21, 2013·Blood·Judith C W Marsh, Austin G Kulasekararaj
Jul 13, 2011·The Korean Journal of Hematology·Gak-Won YunDeog-Yeon Jo
Apr 29, 2016·Blood·Seishi Ogawa
Oct 16, 2016·Wiener klinische Wochenschrift·Wolfgang FürederPeter Valent
Nov 11, 2017·International Journal of Molecular Sciences·Roland JacobTony Gutschner
May 31, 2017·Journal of Clinical Pathology·Howard L RibeiroRonald F Pinheiro
Jul 13, 2018·Journal of Clinical and Experimental Hematopathology : JCEH·Hidekazu Kayano
Nov 1, 2018·European Journal of Haematology·Prajwal C Boddu, Tapan M Kadia
Jan 19, 2018·Blood Advances·Judith C W MarshGhulam J Mufti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.